Fosfomycin, trimethoprim/sulfamethoxazole, or ciprofloxacin: which is better for infection prophylaxis with transrectal prostatic biopsy? Multicenter study

Abstract Background Antibiotic prophylaxis is necessary to avoid infectious complications following transrectal ultrasound-guided prostate biopsy (TRUSPB). Till now, there is no consensus or international agreement for the optimal type of antibiotics, particularly after the recommendation against using fluoroquinolones as antibiotic prophylaxis due to their toxicity profile and the increasing bacterial resistance to them. Aim of the work This study aimed to retrospectively compare the efficacy of ciprofloxacin, trimethoprim/sulfamethoxazole, or fosfomycin as perioperative prophylaxis in patients undergoing TRUSBP. Patients and methods We retrospectively analyzed 502 patients who underwent TRUSPB in 2 urological facilities in Egypt and Germany between June 2020 and July 2023 and received either ciprofloxacin ( n : 121), trimethoprim/sulfamethoxazole ( n : 109), or fosfomycin ( n : 272) as antibiotic prophylaxis. Infection rate and site and sepsis rates were assessed within 1 month after the procedure. The causative organism, management protocol, and antibiotics used in management were also studied. Results Infections developed among 3.3% of patients who received fosfomycin, 2.8% who received trimethoprim/sulfamethoxazole, and 0.8% who received ciprofloxacin. The results showed no statistically significant difference among the 3 arms. In Egypt and Germany E. coli was the most common causative Organism. Although there were different management strategies between Egypt and Germany, there was no fatal complication or intensive care admission in the three groups. Conclusions Fosfomycin, ciprofloxacin, and trimethoprim/sulfamethoxazole effectively prevent post-transrectal prostate biopsy infections. Further research is needed to evaluate the efficacy and safety of different types of antibiotics in different populations in which regional variations in pathogen prevalence and resistance patterns should be considered.

Authors

Institutions

Publication Details

Journal
African Journal of Urology
Published
2025-09-26
DOI
https://doi.org/10.1186/s12301-025-00529-3
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Fosfomycin, trimethoprim/sulfamethoxazole, or ciprofloxacin: which is better for infection prophylaxis with transrectal prostatic biopsy? Multicenter study

Amr A. Gaber, Arman Hambaryan, Ahmed Abo Zamel, Rabie M. Ibrahim et al.
African Journal of Urology
Prostate Cancer Diagnosis and Treatment
article

Fosfomycin, trimethoprim/sulfamethoxazole, or ciprofloxacin: which is better for infection prophylaxis with transrectal prostatic biopsy? Multicenter study

Amr A. Gaber, Arman Hambaryan, Ahmed Abo Zamel, Rabie M. Ibrahim, Ossama Mahmoud, Heba Abdellatif, A. Kugler, Hossam Ismail, Ahmed G. Mohamed, Ahmed Yousef, Ahmed Abd El Latif, Mahmoud Eladawy, Noha Mohamed, Hussien Ahmed, Mahmoud Abdallah, Hany F Badawy, samia heikal
article en

Abstract

Abstract Background Antibiotic prophylaxis is necessary to avoid infectious complications following transrectal ultrasound-guided prostate biopsy (TRUSPB). Till now, there is no consensus or international agreement for the optimal type of antibiotics, particularly after the recommendation against using fluoroquinolones as antibiotic prophylaxis due to their toxicity profile and the increasing bacterial resistance to them. Aim of the work This study aimed to retrospectively compare the efficacy of ciprofloxacin, trimethoprim/sulfamethoxazole, or fosfomycin as perioperative prophylaxis in patients undergoing TRUSBP. Patients and methods We retrospectively analyzed 502 patients who underwent TRUSPB in 2 urological facilities in Egypt and Germany between June 2020 and July 2023 and received either ciprofloxacin ( n : 121), trimethoprim/sulfamethoxazole ( n : 109), or fosfomycin ( n : 272) as antibiotic prophylaxis. Infection rate and site and sepsis rates were assessed within 1 month after the procedure. The causative organism, management protocol, and antibiotics used in management were also studied. Results Infections developed among 3.3% of patients who received fosfomycin, 2.8% who received trimethoprim/sulfamethoxazole, and 0.8% who received ciprofloxacin. The results showed no statistically significant difference among the 3 arms. In Egypt and Germany E. coli was the most common causative Organism. Although there were different management strategies between Egypt and Germany, there was no fatal complication or intensive care admission in the three groups. Conclusions Fosfomycin, ciprofloxacin, and trimethoprim/sulfamethoxazole effectively prevent post-transrectal prostate biopsy infections. Further research is needed to evaluate the efficacy and safety of different types of antibiotics in different populations in which regional variations in pathogen prevalence and resistance patterns should be considered.

African Journal of UrologyVol. 31(1)
Beni-Suef University (EG), Cairo University (EG), Sana Klinikum Lichtenberg (DE), Lausitzer Seenland Klinikum (DE), National Water Research Center (EG), Helios Vogtland Klinikum Plauen (DE), Children Cancer Hospital (EG), Cairo University hospitals (EG), Fayoum University (EG), Assiut University (EG)
Openalex Percentile: Top 62%
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.